[{"Assets_0_Q2_USD":131293000.0,"CommonStockSharesOutstanding_0_Q2_shares":13277044.0,"EarningsPerShareBasic_1_Q2_USD":0.04,"EarningsPerShareBasic_2_Q2_USD":0.21,"EarningsPerShareDiluted_1_Q2_USD":0.04,"EarningsPerShareDiluted_2_Q2_USD":0.21,"NetIncomeLoss_1_Q2_USD":506000.0,"NetIncomeLoss_2_Q2_USD":2806000.0,"StockholdersEquity_0_Q2_USD":109412000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":13428000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":13415000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":13220000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":13207000.0,"Ticker":"SRDX","CIK":"924717","name":"SURMODICS INC","OfficialName":"Surmodics Inc. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"609353600.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Electromedical & Electrotherapeutic Apparatus","Market":"NASDAQ","SP500":"nan","filed":"20170428"}]